Drug controller's nod for Omicron-specific mRNA-based vaccine
Updated On: 20 June, 2023 04:47 PM IST | PTI
India`s drug controller has granted emergency use authorisation for the Omicron-specific mRNA-based booster vaccine developed by Gennova Biopharmaceuticals under Mission Covid Suraksha, the Department of Biotechnology said on Tuesday
Representative image/iStock
India's drug controller has granted emergency use authorisation for the Omicron-specific mRNA-based booster vaccine developed by Gennova Biopharmaceuticals under Mission Covid Suraksha, the Department of Biotechnology said on Tuesday.
The Department of Biotechnology (DBT) had facilitated establishing Gennova's mRNA-based next-generation vaccine manufacturing for developing the platform technology from proof of concept till Phase I clinical trial of the prototype vaccine developed against the Wuhan strain, an official statement said.
"GEMCOVAC-OM is an Omicron-specific mRNA-based booster vaccine developed using the indigenous platform technology by Gennova in collaboration with DBT," it said.
"GEMCOVAC-OM getting Emergency Use Authorisation from the office of the Drug Controller General of India is a testimony of our efforts to initiate, nurture and enable this 'pandemic ready' technology," Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd, said.
ADVERTISEMENT
Poll
Will you take intranasal vaccine as a precautionary dose?
GEMCOVAC-OM is a thermostable vaccine which does not require ultra-cold chain infrastructure, making it easy for pan-India deployment.
"Infrastructure to deploy vaccines in India at 2-8 degrees Celsius exists today and this innovation is tailored for the existing established supply-chain infrastructure. The vaccine does not need ultra-low temperature conditions for transport and storage," Science and Technology Minister Jitendra Singh said.
The vaccine is delivered intradermally using a needle-free injection device system.
The project was supported under 'Mission Covid Suraksha', the Indian Covid-19 Vaccine Development Mission' by DBT's dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), for further clinical development and scale up of the prototype vaccine, which received emergency use authorisation in June last year.
Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said GEMCOVAC-OM was developed using the mRNA-based disease agnostic platform technology which can be used to make other vaccines in a relatively short development timeline.
India has now developed two mRNA vaccines against COVID-19 using this rapid-disease-agnostic platform technology.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.
Trending Stories
Latest Web Stories
Latest Photos
06 August, 2026 08:34 PM IST | In Photos: Hiroshima Day Silent Peace March 2026
Preshit Deorukhkar
17 December, 2025 11:56 AM IST | IN PHOTOS: MLAs at Vidhan Bhavan during Maharashtra Legislative Council polls
Asif Ali Sayed
09 September, 2024 09:32 PM IST | IN PHOTOS: People in Mumbai celebrate Gauri Puja during Ganeshotsav
Asif Ali Sayed
09 September, 2024 09:13 PM IST | IN PHOTOS: Mumbai witnesses sunny weather as rains take a break
Asif Ali Sayed
Latest Videos
ADVERTISEMENT
Mid-day Fast
Latest Headlines
19 August, 2026 11:50 AM IST | Test Tushar
12 August, 2026 07:33 PM IST | Oshin Fernandes
10 August, 2026 11:49 AM IST | Makepeace Sitlhou
06 August, 2026 08:34 PM IST | Preshit Deorukhkar